Literature DB >> 25390761

Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: comparative effects of amlodipine and valsartan.

Turgay Celık1, Sevket Balta, Murat Karaman, Seyıt Ahmet Ay, Saıt Demırkol, Cengız Ozturk, Mustafa Dınc, Hılmı U Unal, M Ilker Yılmaz, Selım Kılıc, Gulcan Kurt, A Tas, Atıla Iyısoy, Fosca Quartı-Trevano, Francesco Fıcı, Guıdo Grassı.   

Abstract

Vascular inflammation plays an important role in the pathophysiology of hypertension and high levels of endocan may reflect ongoing vascular inflammation in hypertensive patients. In the present hypothesis-generating study, we aimed at investigating the comparative effects of amlodipine and valsartan on endocan levels in newly diagnosed hypertensive patients. The study population consisted of 37 untreated hypertensive patients who were randomized to the two treatment arms. After baseline assessment, each patient was randomly allocated to either 10 mg daily of amlodipine (n = 18, 7 males) or 160 mg daily of valsartan (n = 19, 3 males) and treated for a 3-month period. Sphygmomanometric blood pressure (BP) and serum endocan were measured before and every 2 weeks during drug treatment. There was no statistically significant difference between the two treatment arms as far as baseline socio-demographic and clinical characteristics are concerned. After a 3-month treatment period, systolic and diastolic BP values significantly reduced by antihypertensive treatment (p < 0.001). Furthermore, endocan levels were significantly decreased in both treatment arms (p < 0.05). However, amlodipine caused a greater percent decrease in circulating endocan levels compared with valsartan at the end of the treatment period. Both drugs reduced high sensitivity C-reactive protein values. However, the statistical significant difference vs baseline was achieved only in the group treated with amlodipine. No correlation was found between endocan plasma levels and BP reduction. The results of this hypothesis-generating study suggest that amlodipine and valsartan decrease endocan levels in newly diagnosed hypertensive patients. The effects, which are more evident with amlodipine, may contribute to the anti-inflammatory effects exerted by the two drugs on the vascular target.

Entities:  

Keywords:  Amlodipine; endocan; endothelium; valsartan; vascular inflammation

Mesh:

Substances:

Year:  2014        PMID: 25390761     DOI: 10.3109/08037051.2014.972816

Source DB:  PubMed          Journal:  Blood Press        ISSN: 0803-7051            Impact factor:   2.835


  23 in total

Review 1.  Immunity in arterial hypertension: associations or causalities?

Authors:  Hans-Joachim Anders; Marcus Baumann; Giovanni Tripepi; Francesca Mallamaci
Journal:  Nephrol Dial Transplant       Date:  2015-03-11       Impact factor: 5.992

2.  Evaluation of endothelial dysfunction in patients with familial Mediterranean fever: the relationship between the levels of asymmetric dimethylarginine and endocan with carotid intima-media thickness and endothelium-dependent vasodilation.

Authors:  Veysel Ozalper; Muammer Kara; Alpaslan Tanoglu; Ibrahim Cetındaglı; Coskun Ozturker; Yusuf Hancerlı; Serdar Hıra; Kemal Kara; Yavuz Beyazıt; Yusuf Yazgan
Journal:  Clin Rheumatol       Date:  2017-01-10       Impact factor: 2.980

3.  Long Noncoding RNA HOXA-AS3 Integrates NF-κB Signaling To Regulate Endothelium Inflammation.

Authors:  Xinxing Zhu; Duchu Chen; Yanli Liu; Jinjin Yu; Liang Qiao; Shuibin Lin; Demeng Chen; Genshen Zhong; Xifeng Lu; Yize Wang; Jieqi Wen; Xinqi Zhong; Yizhou Jiang
Journal:  Mol Cell Biol       Date:  2019-09-11       Impact factor: 4.272

4.  Endocan, Novel Potential Biomarker for Systemic Sclerosis: Results of a Pilot Study.

Authors:  Paul Bălănescu; Anca Lădaru; Eugenia Bălănescu; Theodor Voiosu; Cristian Băicuş; Gheorghe Andrei Dan
Journal:  J Clin Lab Anal       Date:  2015-09-01       Impact factor: 2.352

Review 5.  Vascular endothelial dysfunction and pharmacological treatment.

Authors:  Jin Bo Su
Journal:  World J Cardiol       Date:  2015-11-26

6.  Serum Endocan Levels in Children with Febrile Neutropenia.

Authors:  Eylem Kiral; Ener Cagri Dinleyici; Ayse Bozkurt-Turhan; Ozcan Bor; Yurdanur Akgun; Necat Akdeniz Akgun
Journal:  Hematol Rep       Date:  2016-03-17

7.  Serum Endocan Levels Associated with Hypertension and Loss of Renal Function in Pediatric Patients after Two Years from Renal Transplant.

Authors:  Livia Victorino de Souza; Vanessa Oliveira; Aline Oliveira Laurindo; DelmaRegına Gomes Huarachı; Paulo Cesar Koch Nogueira; Luciana de Santis Feltran; José Osmar Medina-Pestana; Maria do Carmo Franco
Journal:  Int J Nephrol       Date:  2016-12-19

8.  Serum endocan levels in women with restless legs syndrome.

Authors:  Kenan Celik; Mehmet A Cikrikcioglu; Gulistan Halac; Elif Kilic; Siddika Ayhan; Nihal Ozaras; Kemal Yildiz; Rabia S Yildiz; Mehmet Zorlu; Cumali Karatoprak; Mustafa Cakirca; Muharrem Kiskac
Journal:  Neuropsychiatr Dis Treat       Date:  2015-11-19       Impact factor: 2.570

9.  Endocan and Non-Dipping Circadian Pattern in Newly Diagnosed Essential Hypertension.

Authors:  Tolga Çimen; Murat Bilgin; Ahmet Akyel; Mehmet Ali Felekoğlu; Ali Nallbani; Şeyda Özdemir; Gönül Erden; Alpaslan Öztürk; Mehmet Doğan; Ekrem Yeter
Journal:  Korean Circ J       Date:  2016-11-01       Impact factor: 3.243

10.  Plasma endocan level and prognosis of immunoglobulin A nephropathy.

Authors:  Yu Ho Lee; Jin Sug Kim; Se-Yun Kim; Yang Gyun Kim; Ju-Young Moon; Kyung-Hwan Jeong; Tae Won Lee; Chun-Gyoo Ihm; Sang-Ho Lee
Journal:  Kidney Res Clin Pract       Date:  2016-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.